CA-XSOLLA
Shurick Agapitov, a visionary author and the Founder of Xsolla unveiled his groundbreaking new book, "Once Upon Tomorrow," today. This pioneering work offers a transformative and aspirational vision of the Metaverse, contrasting markedly with mainstream narratives. Agapitov's book is a thought-provoking journey into the possibilities and potential of the Metaverse, providing a unique perspective diverging from the views often presented at industry conferences and by technology CEOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130496363/en/
(Graphic: Business Wire)
"In 'Once Upon Tomorrow,' I present a vision of the Metaverse as a vast, inclusive, and transformative space. It's not just a digital frontier but a realm where creativity, innovation, and empowerment converge. This book is my invitation to creators, thinkers, and dreamers across the globe to join in shaping a future where technology amplifies human potential and fosters a world of limitless possibilities. The Metaverse, as I see it, is not about control or confinement but about unleashing the collective creativity and entrepreneurial spirit inherent in all of us," said Shurick Agapitov, Founder of Xsolla and acclaimed author of "Once Upon Tomorrow."
"Once Upon Tomorrow" delves into the untapped potential of the Metaverse, highlighting its capacity to unite emerging and legacy brands, create unforgettable consumer experiences, and enrich cultures globally. Agapitov emphasizes the Metaverse's role in democratizing opportunities and equal access to cutting-edge technologies. His vision extends beyond mere technological innovation, underscoring the Metaverse's potential to empower and reward content creators across the globe. The book also highlights the significant impact of the Metaverse on education, offering hope and opportunities for both children and adults worldwide. Agapitov advocates for a decentralized Metaverse moving away from Silicon Valley's dominance, placing control, profit potential, and freedom in the hands of creative communities.
"Once Upon Tomorrow" is more than just a book about the Metaverse; it's a roadmap to a future where technology serves humanity in all its diversity, fostering financial, social, and creative inclusivity. Agapitov envisions a future where every consumer-facing industry, from fashion to healthcare and entertainment, is transformed. The book also explores the potential impact of the Metaverse on business-to-business sectors, education, city planning, inter-government relations, and non-profit efforts.
Agapitov's insight into the evolution of technology, from the early days of Instagram and Snapchat to the future of immersive applications, is a key highlight of the book. He discusses the roles of various technology stakeholders, including internet hosting providers, website developers, cloud computing experts, infrastructure engineers, and the ongoing need for advanced networking and hardware. "Once Upon Tomorrow" is a visionary piece that invites readers to rethink the Metaverse and its limitless potential.
For additional information and to purchase please visit: onceupontomorrow.com
About Shurick Agapitov
As the founder of Xsolla, Inc., Shurick Agapitov is a highly respected innovator and advisor in gaming, Web3, Metaverse, and fintech. His trailblazing video game company integrates blockchain technology, providing developers with advanced tools and services for more effective game operations and sales. With a global presence, including offices in Los Angeles, Berlin, and Seoul, Xsolla, under Shurick’s leadership, is shaping the future of gaming and the Metaverse, fostering a more decentralized and inclusive industry.
For additional information about Shurick Agapitov please visit: themarque.com or LinkedIn.com
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130496363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom